E
ARQT icon

Ergoteles’s Arcutis Biotherapeutics ARQT Stock Holding History

Ergoteles’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-30,296
Closed -$333K – 1038
2023
Q1 		$333K Sell
30,296
-4,369
-13% -$63.2K 0.01% 866
2022
Q4 		$513K Buy
+34,665
New +$606K 0.02% 689

Other funds holding ARQT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Ergoteles's ARQT Position: Q2 2023 in Review

Ergoteles sold out of Arcutis Biotherapeutics (ARQT) in Q2 2023, closing a stake of 30,296 shares — an estimated $333K sold.

Ergoteles first reported a position in ARQT in Q4 2022 and held it in 2 quarters. The position peaked at $513K in Q4 2022. 136 funds tracked by Wall St. Rank hold ARQT as of Q2 2023.

  • Ergoteles reported no remaining Arcutis Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 30,296 Arcutis Biotherapeutics shares in Q2 2023, an estimated $333K.
  • Ergoteles first reported a position in Arcutis Biotherapeutics in Q4 2022 and held it in 2 quarters.
  • Ergoteles's Arcutis Biotherapeutics position peaked at $513K in Q4 2022.
  • 136 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.